N41mab-vcMMAE

N/A

Report date: 2024/02/05 14:03:36

Base Information

Drug NameN41mab-vcMMAE

Drug Alias NameN41mab-vcMMAE

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAE payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionAnti-NECTIN4Tubulin polymerisation inhibitors

TargetsNectin-4Tubulin

Therapy Area/IndicationsTriple Negative Breast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryFrance

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesAix-Marseille University

China Registration ClassN/A

Develop Information

Active CompaniesAix-Marseille University

Inactive CompaniesN/A

Active IndicationsTriple Negative Breast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A